To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of ADHD in Euthymic Adults With Bipolar I/II Disorder.
Phase of Trial: Phase IV
Latest Information Update: 01 Sep 2013
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder; Bipolar I disorders; Bipolar II disorders
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 31 May 2012 Actual patient number added 45 according to ClinicalTrials.gov.
- 31 May 2012 Actual End Date added to 1 Jan 2012 as reported by ClinicalTrials.gov.